Tributary Capital Management, LLC Incyte Corp Transaction History

Tributary Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 06, 2022	SELL	$63.34 - $74.11 $760,080 - $889,320	-12,000 Closed	0 $0
Q3 2021 Oct 14, 2021	SELL	$68.67 - $84.02 $206,010 - $252,060	-3,000 Reduced 20.0%	12,000 $825,000
Q4 2020 Jan 19, 2021	SELL	$80.74 - $97.7 $258,367 - $312,640	-3,200 Reduced 17.58%	15,000 $1.31 Million
Q3 2020 Oct 13, 2020	SELL	$85.07 - $109.69 $110,590 - $142,597	-1,300 Reduced 6.67%	18,200 $1.63 Million
Q2 2020 Jul 20, 2020	BUY	$74.18 - $108.93 $318,974 - $468,399	4,300 Added 28.29%	19,500 $2.03 Million
Q1 2020 Apr 14, 2020	SELL	$63.18 - $85.97 $246,402 - $335,283	-3,900 Reduced 20.42%	15,200 $1.11 Million
Q4 2019 Jan 16, 2020	SELL	$73.04 - $95.72 $87,648 - $114,864	-1,200 Reduced 5.91%	19,100 $1.67 Million
Q3 2019 Oct 15, 2019	SELL	$72.82 - $86.52 $21,845 - $25,956	-300 Reduced 1.46%	20,300 $1.51 Million
Q4 2018 Jan 23, 2019	SELL	$58.5 - $69.94 $87,750 - $104,910	-1,500 Reduced 6.79%	20,600 $1.31 Million
Q3 2018 Oct 16, 2018	BUY	$61.75 - $74.23 $154,375 - $185,575	2,500 Added 12.76%	22,100 $1.53 Million
Q2 2018 Jul 25, 2018	BUY	$60.85 - $83.98 $1.19 Million - $1.65 Million	19,600 New	19,600 $1.31 Million

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Tributary Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Tributary Capital Management, LLC with notifications on news.